Elena Ratner

8.5k total citations
145 papers, 2.4k citations indexed

About

Elena Ratner is a scholar working on Oncology, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Elena Ratner has authored 145 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 54 papers in Reproductive Medicine and 45 papers in Obstetrics and Gynecology. Recurrent topics in Elena Ratner's work include Ovarian cancer diagnosis and treatment (47 papers), Endometrial and Cervical Cancer Treatments (31 papers) and HER2/EGFR in Cancer Research (22 papers). Elena Ratner is often cited by papers focused on Ovarian cancer diagnosis and treatment (47 papers), Endometrial and Cervical Cancer Treatments (31 papers) and HER2/EGFR in Cancer Research (22 papers). Elena Ratner collaborates with scholars based in United States, Italy and United Kingdom. Elena Ratner's co-authors include Peter E. Schwartz, Alessandro D. Santin, Masoud Azodi, Thomas Rutherford, Stefania Bellone, Natália Buza, Dan‐Arin Silasi, Z. Ping Lin, Mary Jane Minkin and Emiliano Cocco and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Elena Ratner

137 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elena Ratner United States	30	1.0k	679	654	622	307	145	2.4k
Bhavana Pothuri United States	30	1.2k 1.2×	683 1.0×	1.1k 1.6×	1.1k 1.7×	363 1.2×	203	3.4k
Christine Walsh United States	30	874 0.8×	687 1.0×	845 1.3×	1.0k 1.6×	349 1.1×	93	2.6k
Whitfield B. Growdon United States	31	616 0.6×	921 1.4×	545 0.8×	966 1.6×	233 0.8×	139	2.7k
Roisin E. O’Cearbhaill United States	25	1.2k 1.2×	605 0.9×	471 0.7×	834 1.3×	348 1.1×	174	2.4k
Marcus Q. Bernardini Canada	30	834 0.8×	1.2k 1.8×	723 1.1×	1.3k 2.1×	329 1.1×	134	3.1k
Maria Luisa Gasparri Italy	27	452 0.4×	928 1.4×	651 1.0×	866 1.4×	220 0.7×	100	2.3k
Paul Smith United Kingdom	26	1.2k 1.1×	426 0.6×	534 0.8×	409 0.7×	257 0.8×	65	2.6k
Tomoyasu Kato Japan	27	611 0.6×	973 1.4×	986 1.5×	802 1.3×	369 1.2×	194	2.9k
Carolyn Krasner United States	26	1.0k 1.0×	449 0.7×	627 1.0×	1.2k 1.9×	528 1.7×	107	2.5k
Charles A. Kunos United States	28	724 0.7×	642 0.9×	432 0.7×	444 0.7×	412 1.3×	138	2.1k

Countries citing papers authored by Elena Ratner

Since Specialization

Citations

This map shows the geographic impact of Elena Ratner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Ratner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Ratner more than expected).

Fields of papers citing papers by Elena Ratner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Ratner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Ratner. The network helps show where Elena Ratner may publish in the future.

Co-authorship network of co-authors of Elena Ratner

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Ratner. A scholar is included among the top collaborators of Elena Ratner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Ratner. Elena Ratner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bellone, Stefania, Tobias M.P. Hartwich, Blair McNamara, et al.. (2025). Preclinical Activity of Datopotamab Deruxtecan, an Antibody–Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications. 5(5). 774–782. 1 indexed citations

Erfani, Hadi, Carolyn Haunschild, Mitchell Clark, et al.. (2025). Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study. International Journal of Gynecological Cancer. 104440–104440.

Bellone, Stefania, Tobias M.P. Hartwich, Blair McNamara, et al.. (2025). Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal of Molecular Sciences. 26(18). 8924–8924.

Liu, Joyce F., Stéphanie Gaillard, Andrea E. Wahner Hendrickson, et al.. (2024). Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO Precision Oncology. 8(8). e2300693–e2300693. 6 indexed citations

Erickson, Britt, Danielle Enserro, Heather A. Lankes, et al.. (2024). Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026).. Journal of Clinical Oncology. 42(16_suppl). TPS5641–TPS5641. 4 indexed citations

Altwerger, Gary, et al.. (2024). Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients. PLoS ONE. 19(7). e0305273–e0305273. 3 indexed citations

Han, Chanhee, Blair McNamara, Stefania Bellone, et al.. (2023). The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology. 170. 172–178. 5 indexed citations

Roberts, Cai M., et al.. (2023). Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib. Cancers. 15(15). 3919–3919. 4 indexed citations

Zeybek, Burak, Emily Webster, Joan Tymon‐Rosario, et al.. (2021). Financial toxicity in patients with gynecologic malignancies: a cross sectional study. Journal of Gynecologic Oncology. 32(6). e87–e87. 14 indexed citations

10.

Buza, Natália, Pei Hui, Stefania Bellone, et al.. (2020). Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. Gynecologic Oncology Reports. 32. 100554–100554. 6 indexed citations

11.

Bellone, Stefania, Natália Buza, Jungmin Choi, et al.. (2018). Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clinical Cancer Research. 24(14). 3282–3291. 35 indexed citations

12.

Lin, Z. Ping, Yong-Lian Zhu, Ying‐Chun Lo, et al.. (2018). Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. PLoS ONE. 13(11). e0207399–e0207399. 28 indexed citations

13.

Wong, Serena, Elena Ratner, & Natália Buza. (2018). Intra‐operative evaluation of prophylactic hysterectomy and salpingo‐oophorectomy specimens in hereditary gynaecological cancer syndromes. Histopathology. 73(1). 109–123. 6 indexed citations

14.

Altwerger, Gary, Esther Borges Florsheim, Gulden Menderes, et al.. (2018). Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal of Cancer Research and Clinical Oncology. 144(12). 2449–2456. 20 indexed citations

15.

Altwerger, Gary, Gregory M. Gressel, Diana P. English, et al.. (2016). Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. Gynecologic Oncology. 144(1). 77–82. 30 indexed citations

16.

Ferrari, Francesca, Stefania Bellone, Jonathan Black, et al.. (2015). Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Journal of Experimental & Clinical Cancer Research. 34(1). 123–123. 31 indexed citations

17.

Lin, Z. Ping, et al.. (2014). Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors. Molecular Cancer Research. 12(3). 381–393. 34 indexed citations

18.

Pérez, Jimena, et al.. (2013). miRNA array analysis determines miR-205 is overexpressed in head and neck squamous cell carcinoma and enhances cellular proliferation. 1(6). 153–162. 3 indexed citations

19.

Erekson, Elisabeth A., Elena Ratner, Lisa M. Walke, & Terri R. Fried. (2012). Gynecologic Surgery in the Geriatric Patient. Obstetrics and Gynecology. 119(6). 1262–1269. 9 indexed citations

20.

Keane, Florence K. & Elena Ratner. (2010). The KRAS-Variant Genetic Test As a Marker of Increased Risk of Ovarian Cancer.. PubMed Central. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact